PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
about
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian CancerDietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancerClinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm.EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
P2860
Q33606561-4D145684-2034-438A-A40F-F55FA3DE57E0Q33906118-C3E206B8-C1C2-4E92-9306-A0F512AB0BF8Q36320168-FFDE52F6-8A70-4757-9ABF-8C5BA8BAAE78Q38856683-7EA4EEB8-4576-4F85-A25D-7EE867F79562Q41006936-F57648FB-C3BF-45ED-9244-490B9CF9FD58Q47142663-E9BBDE20-062F-4782-A9BB-A658626F8D8BQ48325256-6683F36B-655A-4C4D-97E9-4890D6859062
P2860
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
@en
type
label
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
@en
prefLabel
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
@en
P2860
P356
P1476
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
@en
P2093
Fatima El-Khouly
Jonathan A Ledermann
P2860
P2888
P356
10.1038/BJC.2015.395
P407
P478
113 Suppl 1
P577
2015-12-01T00:00:00Z
2015-12-15T00:00:00Z